fda warning letters glp-1 september 2025 news Novo Hit With Letter for Unreported Ozempic Safety Signals Why the FDA Issued 30
Description
Retatrutide, a GIP/GLP-1/glucagon receptor triagonist for obesity
Semaglutide has years of post-marketing surveillance data from millions of users
Mazdutide overall appears to achieve superior weight loss, in shorter periods of times compared to GLP1R agonists
Journal of Cellular Physiology
In severe cases hypoglycemia can cause confusion, excess sweating, disturbed sleep, seizures and loss of consciousness
